The decision not to pursue a take-private deal means that Bausch + Lomb will continue to operate as a public entity. This could maintain the current market perception and valuation of BHC, as no significant ownership changes are occurring. The impact on BHC's stock price is likely neutral in the short term as the status quo is maintained.